Raffaella Lombardi1. 1. Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, Texas Heart Institute at St Luke’s Episcopal Hospital, Houston, Texas 77030, USA. Raffaella.Lombardi@uth.tmc.edu
Abstract
PURPOSE OF REVIEW: Sudden cardiac death (SCD) affects a significant percentage of young individuals. SCDs are due to genetic heart disorders, such as cardiomyopathies and channelopathies. In the present review, we will describe the recent advancements in understanding the genetic and molecular basis of hereditary cardiac diseases. RECENT FINDINGS: Considerable progress has been made in identification of new genes associated with monogenic familial arrhythmogenic syndromes, giving the opportunity to delineate their molecular pathogenesis and identify potential targets for therapeutic intervention. Research discoveries and rapidly dropping costs of DNA sequencing technologies have resulted in availability of genetic testing panels. SUMMARY: Advances in genetic sequencing technology are expected to significantly impact the clinical practice in the near future. Genetic testing represents a powerful tool for cause determination of arrhythmogenic cardiac diseases, efficient screening of family members, possible risk stratification and treatment choices. However, specific expertise is required for rational ordering and correct interpretation of the genetic screening results.
PURPOSE OF REVIEW: Sudden cardiac death (SCD) affects a significant percentage of young individuals. SCDs are due to genetic heart disorders, such as cardiomyopathies and channelopathies. In the present review, we will describe the recent advancements in understanding the genetic and molecular basis of hereditary cardiac diseases. RECENT FINDINGS: Considerable progress has been made in identification of new genes associated with monogenic familial arrhythmogenic syndromes, giving the opportunity to delineate their molecular pathogenesis and identify potential targets for therapeutic intervention. Research discoveries and rapidly dropping costs of DNA sequencing technologies have resulted in availability of genetic testing panels. SUMMARY: Advances in genetic sequencing technology are expected to significantly impact the clinical practice in the near future. Genetic testing represents a powerful tool for cause determination of arrhythmogenic cardiac diseases, efficient screening of family members, possible risk stratification and treatment choices. However, specific expertise is required for rational ordering and correct interpretation of the genetic screening results.
Authors: Olallo Sanchez; Oscar Campuzano; Anna Fernández-Falgueras; Georgia Sarquella-Brugada; Sergi Cesar; Irene Mademont; Jesus Mates; Alexandra Pérez-Serra; Monica Coll; Ferran Pico; Anna Iglesias; Coloma Tirón; Catarina Allegue; Esther Carro; María Ángeles Gallego; Carles Ferrer-Costa; Anna Hospital; Narcís Bardalet; Juan Carlos Borondo; Albert Vingut; Elena Arbelo; Josep Brugada; Josep Castellà; Jordi Medallo; Ramon Brugada Journal: PLoS One Date: 2016-12-08 Impact factor: 3.240